Concepedia

L. Timlin

LT

Statistics

Publications

7

Citations

206

H-Index

7

Active since

2009

Affiliations

Health Economics and Outcomes Research (United Kingdom)(Current)

Eli Lilly (United Kingdom)

St. Hedwig-Krankenhaus

University Medical Center Utrecht

Eli Lilly (Germany)

L. Timlin is an author at Health Economics and Outcomes Research (United Kingdom) specializing in pharmacoeconomics, cost-effectiveness analysis, and urinary incontinence.

ORCID

Publications per year

2009–2018

7

Publications

7

Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study*

Stephen C. Jones, Marian Benroubi, Conxa Castell et al. · Current Medical Research and Opinion · 2009 · 47 citations

, , +17

Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK

Amélie Beaudet, James L. Palmer, L. Timlin et al. · Journal of Medical Economics · 2011 · 47 citations · Full text

, , +17

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost‐effectiveness analysis in the German setting

Thomas Mittendorf, Jayne Smith‐Palmer, L. Timlin et al. · Diabetes Obesity and Metabolism · 2009 · 34 citations

, , +17

Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence Symptoms

Douglas G. Tincello, Mark Sculpher, Ralf Tunn et al. · Value in Health · 2009 · 26 citations · Full text

, , +14

Cost-Effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) Study

Borislava Mihaylova, Richard Pitman, Douglas G. Tincello et al. · Value in Health · 2010 · 18 citations · Full text

, , +10

1–5 of 7